Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
Clinical trial NCT06585059 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06585059
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-01
- Primary completion
- 2025-12-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.